Login
$LYEL
$14.65 +$0.35 (2.45%) Live

Ownership

13F as of Q2 2026 · 24.4M shares outstanding

Who owns LYEL?

By type of holder
Institutions 51.8% Insiders 48.2% Everyone else 0.0%
Concentration Top 10 holders own 58.6%
ARCH Venture Management, LLC 13.3% · Innovative Cellular Therapeutics Holdings Ltd 11.5%
Institutional ownership
51.8%
-0.1 pts vs last qtr
Institutional holders
86
+12 vs last qtr
Net shares bought
−10.0K
by institutions in Q2 2026
New / sold out
23 / 11
positions opened vs closed

How is ownership changing?

Institutions, last 8 quarters

Biggest buyers in Q2 2026
  • BlackRock, Inc. +532.5K
  • Opaleye Management Inc. +264.9K

Sign up to see all 5.

Biggest sellers in Q2 2026
  • Foresite Capital Management IV, LLC SOLD OUT −800.4K
  • Citadel Advisors LLC −362.8K

Sign up to see all 5.

Who is planning to sell?

No insider has filed a notice of proposed sale (Form 144) for Lyell Immunopharma, Inc. in the last 12 months.

Is your stake being diluted?

Diluted share count, FY2019–FY2025
+314746.2%
+282.84% a year
Each share's claim on the business
−100.0%
shrank without buying or selling a share
Spent on buybacks vs paid in stock
$12M vs $315M
over 7 fiscal years
Diluted shares, split-adjusted
5.3K8.6M17.3M2019: 5.4K shares'192020: 13.3M shares'202021: 6.8M shares'212022: 12.4M shares'222023: 12.5M shares'232024: 13.1M shares'242025: 17.1M shares'25
Buybacks Stock-based comp
$0$41.0M$81.9M2019 buybacks: $185.0K2019 stock comp: $15.7M'192020 buybacks: $11.8M2020 stock comp: $33.3M'202021 buybacks: $02021 stock comp: $62.2M'212022 buybacks: $02022 stock comp: $81.9M'222023 buybacks: $02023 stock comp: $47.1M'232024 buybacks: $02024 stock comp: $33.1M'242025 buybacks: $02025 stock comp: $41.8M'25

How patient are the owners?

Institutional shares by how long they've been held
5+ years20% 3–5 years14% 1–3 years44% Under 1 year22%
Quarterly turnover
14.2%
of institutional shares changed hands
Top 10 managers, median time held
1.5 years

Super Investors

Investment managers reporting LYEL on Form 13F
AV
ARCH Venture Management, LLC
Shares
3.2M
% of company
13.29%
Change vs last qtr
Unchanged
Held since
2025
GP
GSK plc
Shares
1.5M
% of company
6.19%
Change vs last qtr
Unchanged
Held since
Q4 '25

28 more super investors behind a free account

See every manager holding Lyell Immunopharma, Inc., how their position has changed, and how long they've held it.

Sign up free

Institutional Funds

Mutual funds and ETFs reporting LYEL on Form N-PORT; together they hold 7.8% of the company
VT
Position value
$8.49M
% of company
2.47%
% of the fund
0.00%
As of
June 30, 2026
IR
iShares Trust
Position value
$3.19M
% of company
0.93%
% of the fund
0.00%
As of
June 30, 2026

23 more funds behind a free account

See every fund holding Lyell Immunopharma, Inc. and how much of the fund the position is.

Sign up free

Insiders and 5%+ holders

From Forms 3/4/5 and Schedules 13D/G
IC
Innovative Cellular Therapeutics Holdings Ltd
Insider
Shares
2.8M
% of company
11.54%
Change vs last qtr
—
Held since
—
NR
Nelsen Robert
Insider
Shares
2.7M
% of company
11.18%
Change vs last qtr
—
Held since
—

12 more holders behind a free account

See every insider and 5%+ holder of Lyell Immunopharma, Inc..

Sign up free

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support